

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/112001
	Serial No.	10/556,851
	Applicant	Saint-Remy et al.
	371(c) Date	February 1, 2006
	Group	1644
	IDS Filed	February 27, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	US 5,602,015	Feb. 11, 1997	Sudhir
	US 5,744,446	Apr. 28, 1998	Lollar et al.
	US 6,210,675	Apr. 3, 2001	Highfield et al.
	US 7,067,313	Jun. 27, 2006	Jacquemin et al.
	2003/0175268	Sept. 18, 2003	Saint-Remy et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	EP 0 822 255 A2	Feb. 4, 1998	E.P.O.	
	WO 97/26010 A1	Jul. 24, 1997	W.I.P.O.	
	WO 01/04269 A1	Jan. 18, 2001	W.I.P.O.	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Batille et al., "Alloantibody from a Patient with Severe von Willebrand Disease Inhibits von Willebrand Factor-FVIII Interaction," <i>Ann. Hematol.</i> 75:111-115 (1997).
	Begany, "Monoclonal Antibody Improves Sepsis" <i>Pulmonary Reviews.Com</i> Vol. 5, No. 8 (2000).
	Cobb, "Septic Polyarthritis in a Hemophiliac," <i>J. Rheumatol.</i> 11:87-89 (1984).
	Ferenz and Tozzi, "Sepsis due to an Infected Pseudocyst of Hemophilia," <i>Clin. Orthopaedics Rel. Res.</i> 244:254-257 (1989).
	Freeman et al., "The Role of Inflammation in Sepsis and Septic Shock: A Meta-Analysis of Both Clinical and Preclinical Trials of Anti-Inflammatory Therapies," <i>Inflammation: Basic Principles and Clinical Correlates</i> , 3rd Ed., Lippincott Williams & Wilkins, Philadelphia, PA, pp. 965-975 (1999).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/112001
	Serial No.	10/556,851
	Applicant	Saint-Remy et al.
	371(c) Date	February 1, 2006
	Group	1644
	IDS Filed	February 27, 2008

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Gawryl and Hoyer, "Inactivation of Factor VIII Coagulant Activity by Two Different Types of Human Antibodies," <i>Blood</i> 60:1103-1109 (1982)
	Gilles et al., "Anti-Factor VIII Antibodies of Hemophiliac Patients Are Frequently Directed Towards Nonfunctional Determinants and Do Not Exhibit Isotypic Restriction," <i>Blood</i> 82:2452-2461 (1993).
	Gilles et al., "The Arg 2150 His Mutation Within the Factor VIII C1 Domain Eliminates a B Cell Epitope that is Present Only on Factor VIII-Von Willebrand Factor Complexes," <i>Blood</i> 92(Suppl. 1):710a, Abstract 2919 (1998).
	Gilles and Saint-Remy, "Healthy Subjects Produce both Anti-Factor VIII and Specific Anti-Idiotypic Antibodies," <i>J. Clin. Invest.</i> 94:1496-1505 (1994).
	Ingerslev et al., "Applications of Immunoperoxidase Techniques in Specificity Testing of Monoclonal Antibodies (Mabs) Against Von Willebrand Factor (vWf)," <i>Clin. Chem. Acta</i> 174:65-82 (1988).
	Jacquemin et al., "Mechanism and Kinetics of Factor VIII Inactivation: Study with an IgG4 Monoclonal Antibody Derived from a Hemophilia A Patient with Inhibitor," <i>Blood</i> 92:496-506 (1998).
	Jacquemin et al., "A Human Antibody Directed to the Factor VIII C1 Domain Inhibits Factor VIII Cofactor Activity and Binding to von Willebrand Factor," <i>Blood</i> 95:156-163 (2000).
	Jacquemin et al., "Glycosylation of Type 2 Factor VIII Inhibitor Determines Its Maximum Level of FVIII Inhibition," <i>Blood</i> 102:163a (2003). Abstract Only.
	Janeway et al., "The Interaction of the Antibody Molecule with Specific Antigen," <i>Immunobiology</i> , 3 <sup>rd</sup> Ed., Garland Publishing, New York, NY, pp. 3:7-3:11 (1997).
	Janeway et al., "Germinal Center B Cells Undergo V-Region Somatic Hypermutation, and Cells With Mutations that Improve Affinity for Antigen are Selected," <i>Immunobiology</i> , 6th Ed., Garland Science Publishing, New York, NY, pp. 379-381 (2005).
	Kallas et al., "Epitope Specificity of Anti-FVIII Antibodies During Immune Tolerance Therapy With Factor VIII Preparation Containing von Willebrand Factor," <i>Thromb. Res.</i> 107:291-302 (2002).
	Kato et al., "Activity Enhancement of a Lung Cancer-Associated Human Monoclonal Antibody HB4C5 by N-Deglycosylation," <i>Hum. Antibod. Hybridomas</i> 4:9-14 (1993).
	Khurana et al., "The Variable Domain Glycosylation in a Monoclonal Antibody Specific to GnRH Modulates Antigen Binding," <i>Biochem. Biophys. Res. Comm.</i> 234:465-469 (1997).
	Lenting et al., "Identification of a Binding Site for Blood Coagulation Factor IXa on the Light Chain of Human Factor VIII," <i>J. Biol. Chem.</i> 269:7150-7155 (1994).
	Ly et al., "Characterization of an Antibody to Factor VIII in a Patient with Acquired Hemophilia with Circulating Immune Complexes," <i>Scand. J. Haematol.</i> 28:132-140 (1982).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/112001
		Serial No.	10/556,851
		Applicant	Saint-Remy et al.
		371(c) Date	February 1, 2006
		Group	1644
		IDS Filed	February 27, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Martinell et al., "Peritonitis and Septic Shock—An Evaluation of Two Experimental Models in the Rat," <i>Eur. Surg. Res.</i> 17(3):160-166 (1985). Abstract only.
	Merck Manual of Diagnosis and Disease, 17 <sup>th</sup> Ed., Beers et al. (Eds.), Merck Research Laboratories, Whitehouse, NJ, pp. 1143-1147 (1999).
	Near et al., "Characterization of an Anti-Digoxin Antibody Binding Site by Site-Directed <i>In Vitro</i> Mutagenesis," <i>Mol. Immunol.</i> 30(4):369-377 (1993).
	Peerlinck et al., "Antifactor VIII Antibody Inhibiting Allogeneic but not Autologous Factor VIII in Patients with Mild Hemophilia A," <i>Blood</i> 93:2267-2273 (1999).
	Price et al., "Tissue Factor and Tissue Factor Pathway Inhibitor," <i>Anaesthesia</i> 59:483-492 (2004).
	Riedemann and Ward, "Anti-Inflammatory Strategies for the Treatment of Sepsis," <i>Expert Opin. Biol. Ther.</i> 3(2):339-350 (2003).
	Rudikoff et al., "Single Amino Acid Substitution Altering Antigen-Binding Specificity," <i>Proc. Natl. Acad. Sci. USA</i> 79:1979-1983 (1982).
	Saint-Remy, "B- and T-cell Tolerance: From Basic Concepts to Clinical Practice," <i>Haematologica</i> 85(Suppl. to No. 10):93-96 (2000).
	Sato et al., "Humanization of an Anti-Human IL-6 Mouse Monoclonal Antibody Glycosylated in Its Heavy Chain Variable Region," <i>Hum. Antibod. Hybridomas</i> 7(4):175-183 (1996).
	Scandella et al., "Localization of Epitopes for Human Factor VIII Inhibitor Antibodies by Immunoblotting and Antibody Neutralization," <i>Blood</i> 74:1618-1626 (1989).
	Singh et al., "Antithrombotic Effects of Controlled Inhibition of Factor VIII with a Partially Inhibitory Human Monoclonal Antibody in a Murine Vena Cava Thrombosis Model," <i>Blood</i> 99:3235-3240 (2002).
	Taylor et al., "7E3 F(ab') <sub>2</sub> , a Monoclonal Antibody to the Platelet GPIIb/IIIa Receptor, Protects Against Microangiopathic Hemolytic Anemia and Microvascular Thrombotic Renal Failure in Baboons Treated With C4B Binding Protein and a Sublethal Infusion of <i>Escherichia coli</i> ," <i>Blood</i> 89:4078-4084 (1997).
	Wright et al., "Antibody Variable Region Glycosylation: Position Effects on Antigen Binding and Carbohydrate Structure," <i>EMBO J.</i> 10:2717-2723 (1991).
	Yan et al., "Therapeutic Effects of Lysophosphatidylcholine in Experimental Sepsis," <i>Nature Medicine</i> 10:161-167 (2004).
	Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," <i>J. Immunol.</i> 155:1994-2004 (1995).
EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/112001
		Serial No.	10/556,851
		Applicant	Saint-Remy et al.
		371(c) Date	February 1, 2006
		Group	1644
		IDS Filed	February 27, 2008
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Ziegler et al., "Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody Against Endotoxin. A Randomized, Double-Blind, Placebo-Controlled Trial. The HA-1A Sepsis Study Group," <i>New Engl. J. Med.</i> 324:429-436 (1991). Abstract only.
	Written Opinion for PCT/BE2004/000118 mailed February 2, 2005.
	International Search Report for PCT/BE2004/000118 mailed February 2, 2005.
	International Preliminary Report on Patentability for PCT/BE2004/000118 dated December 2, 2005.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	